MX2020003551A - Metodos de tratamiento de dolor agudo o cronico. - Google Patents

Metodos de tratamiento de dolor agudo o cronico.

Info

Publication number
MX2020003551A
MX2020003551A MX2020003551A MX2020003551A MX2020003551A MX 2020003551 A MX2020003551 A MX 2020003551A MX 2020003551 A MX2020003551 A MX 2020003551A MX 2020003551 A MX2020003551 A MX 2020003551A MX 2020003551 A MX2020003551 A MX 2020003551A
Authority
MX
Mexico
Prior art keywords
methods
chronic pain
treating acute
treating
provides methods
Prior art date
Application number
MX2020003551A
Other languages
English (en)
Inventor
David Roberson
Ajay Yekkirala
Michio Painter
Original Assignee
Blue Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blue Therapeutics Inc filed Critical Blue Therapeutics Inc
Publication of MX2020003551A publication Critical patent/MX2020003551A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona métodos para el tratamiento del dolor crónico y agudo. Por ejemplo, la invención proporciona métodos para el tratamiento del dolor neuropático e inflamatorio.
MX2020003551A 2017-10-06 2018-10-08 Metodos de tratamiento de dolor agudo o cronico. MX2020003551A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762569315P 2017-10-06 2017-10-06
PCT/US2018/054884 WO2019071264A1 (en) 2017-10-06 2018-10-08 METHODS FOR TREATING ACUTE OR CHRONIC PAIN

Publications (1)

Publication Number Publication Date
MX2020003551A true MX2020003551A (es) 2020-12-10

Family

ID=65995315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003551A MX2020003551A (es) 2017-10-06 2018-10-08 Metodos de tratamiento de dolor agudo o cronico.

Country Status (9)

Country Link
US (1) US11464772B2 (es)
EP (1) EP3691644A4 (es)
JP (1) JP2020536891A (es)
CN (1) CN111757738A (es)
AU (1) AU2018345909A1 (es)
CA (1) CA3076233A1 (es)
IL (1) IL273500A (es)
MX (1) MX2020003551A (es)
WO (1) WO2019071264A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022155332A1 (en) * 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Methods of treating irritable bowel syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP2006131545A (ja) * 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
CL2007003426A1 (es) * 2006-11-30 2008-04-25 Cenerx Biopharma Inc Compuestos derivados de dialquilaminoalquilo de pigavabina; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos afectivos, depresivos, de ansiedad.
WO2010006299A1 (en) * 2008-07-11 2010-01-14 Regents Of The University Of Minnesota Analgesic agents
WO2010083384A2 (en) * 2009-01-16 2010-07-22 Virginia Commonwealth University Non-peptidyl, potent, and selective mu opioid receptor antagonists
WO2013168011A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
ES2621305T3 (es) * 2012-12-14 2017-07-03 Purdue Pharma Lp Morfinanos espirocíclicos y su uso
CA2894963A1 (en) * 2012-12-14 2014-06-19 Purdue Pharma L.P. Pyridonemorphinan analogs and biological activity on opioid receptors
US10464941B2 (en) * 2015-02-24 2019-11-05 Regents Of The University Of Minnesota Therapeutic compounds

Also Published As

Publication number Publication date
US11464772B2 (en) 2022-10-11
EP3691644A4 (en) 2021-06-30
AU2018345909A1 (en) 2020-04-09
JP2020536891A (ja) 2020-12-17
CN111757738A (zh) 2020-10-09
WO2019071264A1 (en) 2019-04-11
IL273500A (en) 2020-05-31
US20200289500A1 (en) 2020-09-17
EP3691644A1 (en) 2020-08-12
CA3076233A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2020005772A (es) Composiciones que comprenden cepas bacterianas.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2024000300A (es) Anticuerpos antitau y metodos de uso.
MX2018006398A (es) Composiciones que comprenden cepas bacterianas.
MD3804737T2 (ro) Compoziții care conțin tulpini bacteriene
MX2018006399A (es) Composiciones que comprenden cepas bacterianas.
MX2017016398A (es) Composiciones que comprenden cepas bacterianas.
MX2017016560A (es) Composiciones que comprenden cepas bacterianas.
MX2017016525A (es) Composiciones que comprenden cepas bacterianas.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2020006297A (es) Variantes de cd19.
MD3600363T2 (ro) Compoziții cuprinzând tulpini bacteriene
PH12017501864A1 (en) Compositions and methods for treating autism
MX2021006326A (es) Inhibidores de pcna.
MX2018008302A (es) Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.